Endologix Appoints Mike Mathias as Chief Commercial Officer

March 13, 2024—Endologix LLC recently announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.

According to the company, Mathias brings 30 years of experience and a successful track record in leading commercial organizations within the cardiovascular arena, where he has demonstrated exceptional strategic planning, team leadership, and capability for market expansion. He contributed to the advancement of endovascular aneurysm repair and therapies for peripheral vascular disease.

At LimFlow, he led the United States launch of the LimFlow system. Before joining LimFlow, he held various commercial leadership roles at Medtronic for 20 years. He led Medtronic’s Heart Valve Therapies United States commercial operations, launching transcatheter aortic valve replacement therapies.

“Joining Endologix at such a critical juncture is an honor,” commented Mathias in the press release. “I am excited to apply my experience to innovate and join the leadership team of a company that stands at the forefront of interventional vascular therapies. Together, we will work to enhance our commercial strategy, ensuring success for our commercial teams and the organization as a whole.”

Additionally, Matt Thompson, MD, President and CEO of Endologix, commented, “We are delighted to bring such an experienced and successful leader into Endologix. Mike is uniquely qualified to lead our global commercial team and continue the strategic development of our commercial plans. His extensive experience and success in launching pioneering therapies in the medical device industry make him an invaluable asset to our senior leadership team. We believe that with Mike’s leadership, our global sales, business development, and marketing teams will continue to thrive.”